Header Logo

Connection

LOIS M RAMONDETTA to Humans

Back to Details
This is a "connection" page, showing publications LOIS M RAMONDETTA has written about Humans.
LOIS M RAMONDETTA
Connection Strength
0.673
Humans
  1. Endometrial cancer patients understanding and interest in weight loss surgery. Gynecol Oncol. 2023 08; 175:88-92.
    View in: PubMed
    Score: 0.017
  2. Knowledge matters and?empowers: HPV vaccine advocacy among HPV-related cancer survivors. Support Care Cancer. 2020 May; 28(5):2407-2413.
    View in: PubMed
    Score: 0.013
  3. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530.
    View in: PubMed
    Score: 0.013
  4. Team-Based Learning Module for Undergraduate Medical Education: a Module Focused on the Human Papilloma Virus to Increase Willingness to Vaccinate. J Cancer Educ. 2019 04; 34(2):357-362.
    View in: PubMed
    Score: 0.013
  5. Relationship Between Intent to Vaccinate and the Education and Knowledge of Human Papillomavirus Among Medical School Faculty and Students in Texas. Tex Med. 2019 Jan 01; 115(1):e1.
    View in: PubMed
    Score: 0.013
  6. Human Papillomavirus: From Basic Science to Clinical Management for Preclinical Medical Students. MedEdPORTAL. 2018 12 21; 14:10787.
    View in: PubMed
    Score: 0.013
  7. Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. Gynecol Oncol. 2018 02; 148(2):342-348.
    View in: PubMed
    Score: 0.012
  8. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol Oncol. 2017 04; 145(1):108-113.
    View in: PubMed
    Score: 0.011
  9. Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. Support Care Cancer. 2017 06; 25(6):1985-1991.
    View in: PubMed
    Score: 0.011
  10. Human Papillomavirus Vaccine Uptake in Texas Pediatric Care Settings: A Statewide Survey of Healthcare Professionals. J Community Health. 2017 Feb; 42(1):58-65.
    View in: PubMed
    Score: 0.011
  11. Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):500-5.
    View in: PubMed
    Score: 0.010
  12. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
    View in: PubMed
    Score: 0.010
  13. Assessment of sexual activity and dysfunction in medically underserved women with gynecologic cancers. Gynecol Oncol. 2015 Oct; 139(1):134-40.
    View in: PubMed
    Score: 0.010
  14. Acceptability of self-sample human papillomavirus testing among medically underserved women visiting the emergency department. Gynecol Oncol. 2015 Aug; 138(2):317-22.
    View in: PubMed
    Score: 0.010
  15. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol. 2015 Aug; 138(2):388-93.
    View in: PubMed
    Score: 0.010
  16. Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
    View in: PubMed
    Score: 0.010
  17. Surprising results regarding MASCC members' beliefs about spiritual care. Support Care Cancer. 2013 Nov; 21(11):2991-8.
    View in: PubMed
    Score: 0.009
  18. What is the appropriate approach to treating women with incurable cervical cancer? J Natl Compr Canc Netw. 2013 Mar 01; 11(3):348-55.
    View in: PubMed
    Score: 0.008
  19. Importance of adrenergic pathways in women's cancers. Cancer Biomark. 2013; 13(3):145-54.
    View in: PubMed
    Score: 0.008
  20. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):451-5.
    View in: PubMed
    Score: 0.008
  21. "Doctor, what did I do to deserve this?". Palliat Support Care. 2011 Dec; 9(4):425-7.
    View in: PubMed
    Score: 0.008
  22. Work related stress among gynecologic oncologists. Gynecol Oncol. 2011 Nov; 123(2):365-9.
    View in: PubMed
    Score: 0.008
  23. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22.
    View in: PubMed
    Score: 0.007
  24. Religious and spiritual beliefs of gynecologic oncologists may influence medical decision making. Int J Gynecol Cancer. 2011 Apr; 21(3):573-81.
    View in: PubMed
    Score: 0.007
  25. Surgical removal of a gigantic abdominal mass: a multidisciplinary approach. Obstet Gynecol. 2011 Feb; 117(2 Pt 2):508-512.
    View in: PubMed
    Score: 0.007
  26. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34.
    View in: PubMed
    Score: 0.007
  27. The presence of human papillomavirus or p16 in six cases of retroperitoneal carcinoma. Obstet Gynecol. 2010 Nov; 116(5):1042-6.
    View in: PubMed
    Score: 0.007
  28. Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol. 2010 Nov; 119(2):291-4.
    View in: PubMed
    Score: 0.007
  29. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009 May 01; 115(9):1867-74.
    View in: PubMed
    Score: 0.006
  30. Ethnic disparities in cervical cancer survival among Medicare eligible women in a multiethnic population. Int J Gynecol Cancer. 2009 Jan; 19(1):13-20.
    View in: PubMed
    Score: 0.006
  31. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol. 2008 Mar; 111(3):747-51.
    View in: PubMed
    Score: 0.006
  32. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol. 2008 Aug; 62(3):483-9.
    View in: PubMed
    Score: 0.006
  33. Eleven years: the long and winding road. Gynecol Oncol. 2007 Nov; 107(2):166-8.
    View in: PubMed
    Score: 0.006
  34. From technician to professional: integrating spirituality into medical practice. Am J Bioeth. 2007 Jul; 7(7):26-7.
    View in: PubMed
    Score: 0.006
  35. Clinical challenges presented by three simultaneous solid tumors. Gynecol Oncol. 2006 Dec; 103(3):1159-63.
    View in: PubMed
    Score: 0.005
  36. Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecol Oncol. 2006 Nov; 103(2):547-53.
    View in: PubMed
    Score: 0.005
  37. Active coping mediates the association between religion/spirituality and functional well-being in ovarian cancer. Gynecol Oncol. 2005 Dec; 99(3 Suppl 1):S125.
    View in: PubMed
    Score: 0.005
  38. Adult granulosa cell tumors of the ovary in two first-degree relatives. Gynecol Oncol. 2005 Sep; 98(3):502-5.
    View in: PubMed
    Score: 0.005
  39. Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):77-83.
    View in: PubMed
    Score: 0.005
  40. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol. 2005 Jun; 13(2):167-70.
    View in: PubMed
    Score: 0.005
  41. Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J Gynecol Cancer. 2004 Jul-Aug; 14(4):580-8.
    View in: PubMed
    Score: 0.005
  42. A multilevel intervention to promote HPV vaccination among young adults in Texas: protocol for a randomized controlled trial. BMC Public Health. 2024 Jun 05; 24(1):1506.
    View in: PubMed
    Score: 0.005
  43. Spirituality in gynecological oncology: a review. Int J Gynecol Cancer. 2004 Mar-Apr; 14(2):183-201.
    View in: PubMed
    Score: 0.005
  44. Dietary Magnesium Replacement for Prevention of Hypomagnesemia in Patients With Ovarian Cancer Receiving Carboplatin-Based Chemotherapy. JCO Oncol Pract. 2024 Apr; 20(4):517-524.
    View in: PubMed
    Score: 0.005
  45. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 05; 230(5):544.e1-544.e13.
    View in: PubMed
    Score: 0.004
  46. Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival. Curr Oncol Rep. 2024 02; 26(2):147-163.
    View in: PubMed
    Score: 0.004
  47. Spirituality and religion in the "art of dying". J Clin Oncol. 2003 Dec 01; 21(23):4460-2.
    View in: PubMed
    Score: 0.004
  48. Use of a vacuum-assisted closure device in the treatment of recurrent Paget's disease of the vulva. Obstet Gynecol. 2003 Nov; 102(5 Pt 2):1163-6.
    View in: PubMed
    Score: 0.004
  49. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023 11 13; 41(11):1945-1962.e11.
    View in: PubMed
    Score: 0.004
  50. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed m?llerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003 Sep; 90(3):529-36.
    View in: PubMed
    Score: 0.004
  51. Psilocybin-assisted psychotherapy for cancer-related anxiety and depression. Int J Gynecol Cancer. 2023 08 07; 33(8):1327-1328.
    View in: PubMed
    Score: 0.004
  52. Integrative Medicine for Ovarian Cancer. Curr Oncol Rep. 2023 06; 25(6):559-568.
    View in: PubMed
    Score: 0.004
  53. Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2023 05 20; 41(15):2779-2788.
    View in: PubMed
    Score: 0.004
  54. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9.
    View in: PubMed
    Score: 0.004
  55. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 04; 171:141-150.
    View in: PubMed
    Score: 0.004
  56. Mentorship and productivity among gynecologic oncology fellows. J Cancer Educ. 2003; 18(1):15-9.
    View in: PubMed
    Score: 0.004
  57. Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018. Cancer Prev Res (Phila). 2022 11 01; 15(11):777-784.
    View in: PubMed
    Score: 0.004
  58. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure. BMC Cancer. 2022 Sep 01; 22(1):945.
    View in: PubMed
    Score: 0.004
  59. Mixed choriocarcinoma in a postmenopausal patient. Int J Gynecol Cancer. 2002 May-Jun; 12(3):312-6.
    View in: PubMed
    Score: 0.004
  60. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
    View in: PubMed
    Score: 0.004
  61. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021 10; 31(10):1317-1325.
    View in: PubMed
    Score: 0.004
  62. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 Jul; 82(1):156-61.
    View in: PubMed
    Score: 0.004
  63. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
    View in: PubMed
    Score: 0.004
  64. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905.
    View in: PubMed
    Score: 0.004
  65. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 02 22; 4(1):237.
    View in: PubMed
    Score: 0.004
  66. An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas. Sci Rep. 2021 01 19; 11(1):1802.
    View in: PubMed
    Score: 0.004
  67. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.
    View in: PubMed
    Score: 0.004
  68. Using Intervention Mapping to Develop a Provider Intervention to Increase HPV Vaccination in a Federally Qualified Health Center. Front Public Health. 2020; 8:530596.
    View in: PubMed
    Score: 0.004
  69. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
    View in: PubMed
    Score: 0.004
  70. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.004
  71. HPVs Vaccination among Racial/Ethnic Minority College Students: Current Status and Future Direction. J Natl Med Assoc. 2020 Dec; 112(6):639-649.
    View in: PubMed
    Score: 0.004
  72. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
    View in: PubMed
    Score: 0.003
  73. Mesonephric-like Carcinoma of the Endometrium: A Subset of Endometrial Carcinoma With an Aggressive Behavior. Am J Surg Pathol. 2020 04; 44(4):429-443.
    View in: PubMed
    Score: 0.003
  74. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
    View in: PubMed
    Score: 0.003
  75. Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):163-171.
    View in: PubMed
    Score: 0.003
  76. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res. 2000 Jan; 6(1):278-84.
    View in: PubMed
    Score: 0.003
  77. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019 11; 155(2):237-244.
    View in: PubMed
    Score: 0.003
  78. Successful Implementation of a Multidisciplinary Chemotherapy Efficiency Initiative at a Community Hospital. J Oncol Pract. 2019 06; 15(6):e576-e582.
    View in: PubMed
    Score: 0.003
  79. Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin. Oncologist. 2019 06; 24(6):e312-e317.
    View in: PubMed
    Score: 0.003
  80. Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas. J Low Genit Tract Dis. 2019 Apr; 23(2):102-109.
    View in: PubMed
    Score: 0.003
  81. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. Gynecol Oncol. 2019 03; 152(3):452-458.
    View in: PubMed
    Score: 0.003
  82. Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol. 1999 Feb; 180(2 Pt 1):340-1.
    View in: PubMed
    Score: 0.003
  83. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol. 2019 02; 152(2):328-333.
    View in: PubMed
    Score: 0.003
  84. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37.
    View in: PubMed
    Score: 0.003
  85. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients. Pharmacoeconomics. 2018 11; 36(11):1355-1365.
    View in: PubMed
    Score: 0.003
  86. A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas. Anticancer Res. 1998 Nov-Dec; 18(6B):4661-5.
    View in: PubMed
    Score: 0.003
  87. Complete Resection Is Essential in the Surgical Treatment of Gestational Trophoblastic Neoplasia. Int J Gynecol Cancer. 2018 10; 28(8):1453-1460.
    View in: PubMed
    Score: 0.003
  88. Age-Structured Population Modeling of HPV-related Cervical Cancer in Texas and US. Sci Rep. 2018 09 25; 8(1):14346.
    View in: PubMed
    Score: 0.003
  89. Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type. J Minim Invasive Gynecol. 2019 01; 26(1):87-93.
    View in: PubMed
    Score: 0.003
  90. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
    View in: PubMed
    Score: 0.003
  91. Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant. 2018 05; 24(5):1094-1098.
    View in: PubMed
    Score: 0.003
  92. The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. J Pain Symptom Manage. 2018 05; 55(5):1276-1285.
    View in: PubMed
    Score: 0.003
  93. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018 01; 28(1):114-121.
    View in: PubMed
    Score: 0.003
  94. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
    View in: PubMed
    Score: 0.003
  95. Atypical Meigs' syndrome and bilateral ovarian stromal hyperplasia. A case report. J Reprod Med. 1997 Sep; 42(9):603-5.
    View in: PubMed
    Score: 0.003
  96. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.003
  97. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
    View in: PubMed
    Score: 0.003
  98. Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility? Gynecol Oncol. 2017 07; 146(1):74-80.
    View in: PubMed
    Score: 0.003
  99. The Advance Care Planning Readiness Scale: Development and Validation of a Measure of Willingness to Discuss and Acceptance of End-of-Life Care in Gynecologic Cancer Patients. Int J Gynecol Cancer. 2017 05; 27(4):838-846.
    View in: PubMed
    Score: 0.003
  100. End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. J Clin Oncol. 2017 Jun 01; 35(16):1829-1835.
    View in: PubMed
    Score: 0.003
  101. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. Cancer. 2017 06 01; 123(11):1989-1997.
    View in: PubMed
    Score: 0.003
  102. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
    View in: PubMed
    Score: 0.003
  103. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
    View in: PubMed
    Score: 0.003
  104. Percutaneous abscess drainage in gynecologic cancer patients. Gynecol Oncol. 1996 Sep; 62(3):366-9.
    View in: PubMed
    Score: 0.003
  105. Association Between Vaginal Douching and Genital Human Papillomavirus Infection Among Women in the United States. J Infect Dis. 2016 Nov 01; 214(9):1370-1375.
    View in: PubMed
    Score: 0.003
  106. Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Oncol. 2016 09; 142(3):525-30.
    View in: PubMed
    Score: 0.003
  107. Dying well: How equal is end of life care among gynecologic oncology patients? Gynecol Oncol. 2016 Feb; 140(2):295-300.
    View in: PubMed
    Score: 0.003
  108. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 01; 121(19):3444-51.
    View in: PubMed
    Score: 0.003
  109. Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204. Int J Gynecol Cancer. 2015 Feb; 25(2):303-8.
    View in: PubMed
    Score: 0.002
  110. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015 Mar; 16(3):301-11.
    View in: PubMed
    Score: 0.002
  111. Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells. Clin Cancer Res. 2015 Jan 15; 21(2):471-83.
    View in: PubMed
    Score: 0.002
  112. Does death anxiety affect end-of-life care discussions? Int J Gynecol Cancer. 2014 Oct; 24(8):1521-6.
    View in: PubMed
    Score: 0.002
  113. Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol. 2014 Nov; 135(2):244-8.
    View in: PubMed
    Score: 0.002
  114. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014 Sep 01; 32(25):2744-9.
    View in: PubMed
    Score: 0.002
  115. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014 Sep; 134(3):546-51.
    View in: PubMed
    Score: 0.002
  116. Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
    View in: PubMed
    Score: 0.002
  117. Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma. Gynecol Oncol. 2004 Apr; 93(1):272-3; author reply 273-4.
    View in: PubMed
    Score: 0.002
  118. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43.
    View in: PubMed
    Score: 0.002
  119. Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: a feasibility study. Gynecol Oncol. 2014 Jan; 132(1):149-53.
    View in: PubMed
    Score: 0.002
  120. ?-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs. 2013 Nov; 22(11):1359-63.
    View in: PubMed
    Score: 0.002
  121. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
    View in: PubMed
    Score: 0.002
  122. Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. Gynecol Oncol. 2013 Jun; 129(3):513-6.
    View in: PubMed
    Score: 0.002
  123. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
    View in: PubMed
    Score: 0.002
  124. Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer. 2012 Sep; 22(7):1203-7.
    View in: PubMed
    Score: 0.002
  125. Exploring the role of religiosity and spirituality in amniocentesis decision-making among Latinas. J Genet Couns. 2011 Dec; 20(6):660-73.
    View in: PubMed
    Score: 0.002
  126. Ethics consultation on a gynecologic oncology service: an opportunity for physician education. J Cancer Educ. 2011 Mar; 26(1):183-7.
    View in: PubMed
    Score: 0.002
  127. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy. 2011 Mar; 31(3):280-97.
    View in: PubMed
    Score: 0.002
  128. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011 Apr; 204(4):355.e1-7.
    View in: PubMed
    Score: 0.002
  129. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma. Int J Clin Exp Pathol. 2010 Nov 20; 4(1):13-21.
    View in: PubMed
    Score: 0.002
  130. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9.
    View in: PubMed
    Score: 0.002
  131. Caregiver symptom burden: the risk of caring for an underserved patient with advanced cancer. Cancer. 2011 Mar 01; 117(5):1070-9.
    View in: PubMed
    Score: 0.002
  132. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol. 2010 Dec; 119(3):422-5.
    View in: PubMed
    Score: 0.002
  133. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Dec; 119(3):531-7.
    View in: PubMed
    Score: 0.002
  134. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
    View in: PubMed
    Score: 0.002
  135. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 01; 27(28):4649-55.
    View in: PubMed
    Score: 0.002
  136. Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer. 2009 Aug; 19(6):1107-12.
    View in: PubMed
    Score: 0.002
  137. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
    View in: PubMed
    Score: 0.002
  138. Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009 Mar; 200(3):288.e1-8.
    View in: PubMed
    Score: 0.002
  139. In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines. J Oncol Pharm Pract. 2009 Mar; 15(1):35-44.
    View in: PubMed
    Score: 0.002
  140. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract. 2008 Mar; 14(1):31-6.
    View in: PubMed
    Score: 0.001
  141. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):118-25.
    View in: PubMed
    Score: 0.001
  142. In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines. Cancer Chemother Pharmacol. 2008 Jun; 62(1):51-8.
    View in: PubMed
    Score: 0.001
  143. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol. 2006 Dec; 103(3):948-51.
    View in: PubMed
    Score: 0.001
  144. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol Oncol. 2006 Nov; 103(2):518-22.
    View in: PubMed
    Score: 0.001
  145. Active coping mediates the association between religion/spirituality and quality of life in ovarian cancer. Gynecol Oncol. 2006 Apr; 101(1):102-7.
    View in: PubMed
    Score: 0.001
  146. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
    View in: PubMed
    Score: 0.001
  147. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol. 2005 May; 97(2):483-8.
    View in: PubMed
    Score: 0.001
  148. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005 May; 97(2):489-96.
    View in: PubMed
    Score: 0.001
  149. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6.
    View in: PubMed
    Score: 0.001
  150. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004 Oct; 95(1):32-6.
    View in: PubMed
    Score: 0.001
  151. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):442-8.
    View in: PubMed
    Score: 0.001
  152. Malignant mixed M?llerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):786-96.
    View in: PubMed
    Score: 0.001
  153. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol. 2004 Jan; 92(1):314-9.
    View in: PubMed
    Score: 0.001
  154. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
    View in: PubMed
    Score: 0.001
  155. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol. 2003 May; 101(5 Pt 1):941-5.
    View in: PubMed
    Score: 0.001
  156. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 2002 Sep-Oct; 22(5):2945-8.
    View in: PubMed
    Score: 0.001
  157. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53. Gynecol Oncol. 2001 Dec; 83(3):543-8.
    View in: PubMed
    Score: 0.001
  158. Metastatic uterine papillary serous carcinoma to the pericardium. Gynecol Oncol. 2001 Oct; 83(1):135-7.
    View in: PubMed
    Score: 0.001
  159. Survey of female gynecologic oncologists and fellows: balancing professional and personal life. Gynecol Oncol. 2000 Nov; 79(2):309-14.
    View in: PubMed
    Score: 0.001
  160. Quantitative image analysis of MIB-1 reactivity in inflammatory, hyperplastic, and neoplastic endocervical lesions. Int J Gynecol Pathol. 1997 Jan; 16(1):15-21.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.